LePu Biopharma Co., Ltd.
Clinical trials sponsored by LePu Biopharma Co., Ltd., explained in plain language.
A biopharmaceutical company focused on drugs for cardiovascular and metabolic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for pancreatic cancer: experimental drug MRG004A enters final testing phase Results expected Jun 2027 (estimated)
- Can a drug duo shrink Hard-to-Treat tumors? Results expected Aug 2027 (estimated)
-
Experimental drug combo targets Hard-to-Treat head and neck cancer
Disease control CompletedResearchers are testing an experimental drug called MRG003, both by itself and combined with the immunotherapy drug HX008, in people with head and neck squamous cell carcinoma that has come back or spread. Participants have already tried standard treatments like platinum chemothe…
Phase 2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can an Antibody-Drug conjugate crack resistant EGFR lung cancer?
Disease control CompletedResearchers are testing an experimental drug called MRG003 in adults with EGFR-positive advanced non-small cell lung cancer that has worsened after at least two standard treatments. The trial enrolls about 87 participants across multiple sites and gives MRG003 intravenously as a …
Phase 2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Experimental drug targets EGFR-Positive bile duct cancer after standard treatment fails
Disease control CompletedResearchers are testing an experimental drug called MRG003 in adults with biliary tract cancer that is EGFR-positive and cannot be removed by surgery or has spread. The trial enrolls people whose cancer worsened after at least one standard treatment. Everyone receives MRG003 by i…
Phase 2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can an experimental drug shrink advanced solid tumors?
Disease control CompletedThis phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called MRG004A in 39 adults with advanced or metastatic solid tumors that have a specific marker called tissue factor. The goal was to find the safest dose and see if the drug can shrink tumors. Researchers monitored side effects and how well the drug…
Phase 1/2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC